Disclosure Of Entity's Operating Segments [Text Block]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Disclosure of entity's operating segments [text block]
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
2 227 EUR
18 302 EUR
Tax expense (income)
219,000 EUR
263,000 EUR
Profit (loss) before tax
23 221 EUR
18 022 EUR
Profit (loss)
23 003 EUR
23 003 EUR
17 760 EUR
17 760 EUR
Assets
82 054 EUR
91 781 EUR
Cash flows from (used in) operating activities
19 764 EUR
18 252 EUR
Cash flows from (used in) investing activities
507,000 EUR
26,000 EUR
Cash flows from (used in) financing activities
13 324 EUR
10 267 EUR
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.